Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma

Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma

Share This Post

In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people with locally advanced nasopharyngeal cancer (NPC) that has spread or come back. The FDA has approved toripalimab-tpzi as a single treatment for adults with recurrent unresectable or metastatic NPC that progressed during or after platinum-containing chemotherapy.

The efficacy of toripalimab-tpzi with cisplatin and gemcitabine was assessed in JUPITER-02 (NCT03581786), a randomized, multicenter, single region, double-blind, placebo-controlled trial of 289 patients with metastatic or recurrent, locally advanced NPC who had not previously received systemic chemotherapy for recurrent or metastatic disease. Patients were randomly assigned (1:1) to receive toripalimab-tpzi with cisplatin and gemcitabine, followed by toripalimab-tpzi, or placebo with cisplatin and gemcitabine, followed by placebo. For complete prescribing information on chemotherapy regimens, please see the link above.

The key effectiveness outcome measure was progression-free survival (PFS), as determined by a Blinded Independent Review Committee (BIRC) using the RECIST v1.1. Overall survival (OS) was another outcome. The toripalimab-tpzi combination showed a statistically significant improvement in PFS, with a median PFS of 11.7 months versus 8.0 months (hazard ratio [HR] 0.52 [95% CI: 0.36, 0.74], p-value=0.0003). A statistically significant improvement in OS was also seen, with median OS not attained (95% CI: 38.7 months, not estimable) for the toripalimab-tpzi-containing regimen and 33.7 months (95% CI: 27.0, 44.2) for the placebo-containing regimen (HR 0.63 [95% CI: 0.45, 0.89], p=0.0083).

POLARIS-02 (NCT02915432) was an open-label, multicenter, single country, multicohort trial in 172 patients with unresectable or metastatic NPC who had received prior platinum-based chemotherapy or had disease progression within 6 months of completion of platinum-based chemotherapy administered as neoadjuvant, adjuvant, or definitive chemoradiation treatment for locally advanced disease. Patients were given toripalimab-tpzi until disease progression by RECIST v1.1 or intolerable toxicity.

The key efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR), as determined by BIRC using RECIST v1.1. The ORR was 21% (95% CI: 15, 28), with a median DOR of 14.9 months (95% CI: 10.3, not estimable).

Toripalimab-tpzi resulted in immune-mediated adverse responses such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal failure, and skin reactions. Toripalimab-tpzi with cisplatin and gemcitabine caused the most common adverse reactions (≥20%), including nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, dizziness, and malaise. Fatigue, hypothyroidism, and musculoskeletal discomfort were the most prevalent adverse effects (≥20%) reported with toripalimab-tpzi as a single drug.

The recommended dose of toripalimab-tpzi with cisplatin and gemcitabine is 240 mg every three weeks until disease progression, intolerable toxicity, or up to 24 months. The recommended dose of toripalimab-tpzi as a single treatment for previously treated NPC is 3 mg/kg every two weeks until disease progression or unacceptable toxicity.

View full prescribing information for LOQTORZI

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy